Current Opinion in Endocrinology & Diabetes and Obesity最新文献_第3页

Metabolic dysfunction and the use of adjunct medications in type 1 diabetes. 1型糖尿病的代谢功能障碍和辅助药物的使用。

IF 3.5 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-06-01 Epub Date: 2026-03-26 DOI: 10.1097/MED.0000000000000956

Andrew Luk, Yee Seun Cheah, Shivani Misra, Victoria Salem

{"title":"Metabolic dysfunction and the use of adjunct medications in type 1 diabetes.","authors":"Andrew Luk, Yee Seun Cheah, Shivani Misra, Victoria Salem","doi":"10.1097/MED.0000000000000956","DOIUrl":"10.1097/MED.0000000000000956","url":null,"abstract":"Purpose of review: Type 1 diabetes is increasingly complicated by obesity and broader metabolic dysfunction, yet there are barriers to the use of adjunctive pharmacotherapies in this population. This review evaluates the evidence for metformin, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors (SGLT2i) in type 1 diabetes, with a focus on weight loss, glycaemic control, insulin dose requirements and safety.Recent findings: Despite advances, metformin remains the only adjunct widely endorsed in national guidelines for adults with type 1 diabetes. In clinical trials, GLP-1RAs used alongside automated insulin delivery systems demonstrate significant improvements in weight, glucose sensor time-in-range, and total daily insulin dose, without increased risk of diabetic ketoacidosis (DKA). SGLT2i produce more modest weight and HbA1c improvements, and may be associated with an increased risk of DKA, although they have a clear evidence base for independent cardiovascular benefits.Summary: There is an increasing demand by patients and desire by physicians to utilize adjunctive medications in type 1 diabetes. Many patients with type 1 diabetes who are highly likely to benefit from the weight loss and cardiorenal risk reduction effects of these drugs are denied access to them because of putative safety concerns and a dearth of clinical trial evidence in type 1 diabetes. Identifying patients with type 1 diabetes most likely to tolerate and benefit from these agents is a research priority. Real world datasets accounting for the increased off license use of these drugs offers an opportunity to rapidly develop evidence-based guidance.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"115-124"},"PeriodicalIF":3.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13152071/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147519997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prediabetes before pregnancy: implications for risk stratification and research. 妊娠前糖尿病前期：风险分层和研究的意义。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-05-20 DOI: 10.1097/MED.0000000000000964

Saptarshi Bhattacharya, Viswanathan Mohan, Lakshmi Nagendra, Ponnusamy Saravanan

{"title":"Prediabetes before pregnancy: implications for risk stratification and research.","authors":"Saptarshi Bhattacharya, Viswanathan Mohan, Lakshmi Nagendra, Ponnusamy Saravanan","doi":"10.1097/MED.0000000000000964","DOIUrl":"10.1097/MED.0000000000000964","url":null,"abstract":"Purpose of review: This review evaluates whether pregestational prediabetes identifies women at risk of subsequent gestational diabetes mellitus (GDM) and examines its association with maternal and offspring outcomes.Recent findings: Prediabetes is common in women of reproductive age and often precedes GDM. The risk factors for prediabetes and GDM are similar, such as higher BMI, polycystic ovary syndrome, advancing age, and genetic susceptibility. Both conditions denote underlying insulin resistance with limited beta-cell reserve. Preliminary evidence indicates that women with pregestational prediabetes have a higher likelihood of developing GDM. Risk rises progressively with increasing glycemia. Prediabetes is also associated with modestly increased risks of hypertensive disorders of pregnancy and preterm birth, though associations with cesarean delivery, macrosomia, and neonatal outcomes are inconsistent. Glycated hemoglobin in the prediabetes range early in pregnancy is associated with a higher risk of progression to type 2 diabetes than GDM diagnosed at 24-28 weeks. These observations support the view that pregestational prediabetes may emerge as an early marker of metabolic risk with implications extending beyond pregnancy.Summary: Prediabetes represents a state of increased metabolic risk in women planning pregnancy. It lies along a dysglycemic continuum linking preconception glycemic status to GDM and future diabetes. Incorporating glycemic assessment into preconception care may aid GDM risk stratification. However, the evidence is still evolving, and prospective studies are needed to define the role of pregestational prediabetes in predicting maternal, fetal, and long-term outcomes.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":""},"PeriodicalIF":2.7,"publicationDate":"2026-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147971114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The future of triglyceride-regulating therapies and registries. 甘油三酯调节疗法和登记的未来。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-04-01 Epub Date: 2026-02-26 DOI: 10.1097/MED.0000000000000951

Gerald F Watts, Dick C Chan

引用次数: 0

Familial hypercholesterolemia in pregnancy. 妊娠期家族性高胆固醇血症。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-04-01 Epub Date: 2026-02-05 DOI: 10.1097/MED.0000000000000954

Jayanthi Ramanathan, David Sullivan, Gerald Watts, Kirsten Holven, Yee Sian Tiong

{"title":"Familial hypercholesterolemia in pregnancy.","authors":"Jayanthi Ramanathan, David Sullivan, Gerald Watts, Kirsten Holven, Yee Sian Tiong","doi":"10.1097/MED.0000000000000954","DOIUrl":"10.1097/MED.0000000000000954","url":null,"abstract":"Purpose of review: Familial hypercholesterolemia (FH) in pregnancy poses several challenges, requiring a delicate balance between maternal atherosclerotic cardiovascular disease (ASCVD) risk and foetal safety. The review synthesizes current evidence, research gaps, evaluates emerging data on existing lipid-lowering strategies and highlights evolving guideline recommendations.Recent findings: Pregnancy in women with FH has unique considerations for both the mother and the foetus. Data from registries and observational studies indicate that heterozygous FH (HeFH) does not significantly increase foetal adverse outcomes such as congenital malformation, prematurity, low birth weight although there may be a predisposition to early atherogenesis. Maternal risks include preeclampsia, endothelial dysfunction and prothrombotic tendency. Pregnant women with homozygous FH (HoFH) carry a substantially higher morbidity. Management strategies emphasize the need for timely, multidisciplinary care, dietary optimization, selective use of low-dose statins in high-risk HoFH and LDL apheresis for severe cases. Despite emerging evidence of lack of a major teratogenic risk, statins remain contraindicated in most guidelines, during pregnancy and lactation. Time off statins represent a critical gap in ASCVD prevention.Summary: Pregnancy in FH requires a nuanced, stage-specific, individualized approach. Expansion of FH pregnancy registries and prospective studies is essential to guide evidence based care and refine recommendations for the future.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"84-89"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes. 近期临床试验预防乳糜微粒血症综合征急性胰腺炎的经验教训。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-04-01 Epub Date: 2025-11-05 DOI: 10.1097/MED.0000000000000941

Laura D'Erasmo, Daniele Tramontano, Marcello Arca

{"title":"Lessons from recent clinical trials for the prevention of acute pancreatitis in chylomicronemia syndromes.","authors":"Laura D'Erasmo, Daniele Tramontano, Marcello Arca","doi":"10.1097/MED.0000000000000941","DOIUrl":"10.1097/MED.0000000000000941","url":null,"abstract":"Purpose of review: Familial chylomicronemia (FCS) and multifactorial or persistent chylomicronemia syndromes (MCS, pCS) are rare, severe disorders characterized by extreme hypertriglyceridemia and a high risk of recurrent, potentially life-threatening acute pancreatitis. Most patients do not achieve adequate triglyceride control with lifestyle interventions or conventional lipid-lowering therapies, leaving them exposed to persistent complications. This review critically examines emerging therapeutic strategies aimed at improving triglyceride control and reducing acute pancreatitis risk.Recent findings: Advances targeting key molecular regulators of triglyceride metabolism have shown substantial promise. APOC3 inhibitors, including volanesorsen, olezarsen, and plozasiran, achieve up to 80% reductions in triglycerides and markedly lower AP incidence, with favorable safety profiles. ANGPTL3 inhibition via evinacumab may benefit patients with residual lipoprotein lipase activity, including polygenic or mixed chylomicronemia, and could be used during acute sHTG episodes. Lomitapide, acting independently of LPL, is effective in selected FCS patients but requires careful hepatic monitoring. FGF21 analogs, such as pegozafermin, are in early development and show potential for metabolic dysfunction-associated steatotic liver disease, though their impact on acute pancreatitis prevention remains to be established.Summary: These emerging mechanism-based therapies are reshaping the management of severe hypertriglyceridemia, offering targeted approaches to reduce triglycerides and acute pancreatitis risk. Ongoing studies will clarify long-term safety, durability of response, and optimal patient selection, providing a framework for improved clinical outcomes.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"90-100"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia. 抑制血管生成素样蛋白3作为治疗高甘油三酯血症的靶点。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-04-01 Epub Date: 2025-12-17 DOI: 10.1097/MED.0000000000000950

Pablo Corral, Natalia Nardelli, Laura Schreier

{"title":"Inhibition of angiopoietin-like protein 3 as a target for managing hypertriglyceridemia.","authors":"Pablo Corral, Natalia Nardelli, Laura Schreier","doi":"10.1097/MED.0000000000000950","DOIUrl":"10.1097/MED.0000000000000950","url":null,"abstract":"Purpose of review: To summarize recent advances in therapeutic strategies targeting angiopoietin-like protein 3 (ANGPTL3), a central regulator of triglyceride and remnant lipoprotein metabolism, and to discuss the potential of emerging pharmacologic approaches.Recent findings: Several pharmacologic approaches have demonstrated robust lipid-lowering efficacy through ANGPTL3 inhibition. Monoclonal antibodies (evinacumab, SHR-1918) and RNA-based therapies (vupanorsen, zodasiran, solbinsiran) effectively reduce triglycerides, apoprotein B (apoB)-containing lipoproteins, and nonhigh-density lipoprotein cholesterol. The newest and most promising innovation is CRISPR-mediated disruption of ANGPTL3 (CTX310).Summary: ANGPTL3 inhibition represents one of the most powerful current strategies for lowering triglyceride-rich lipoproteins and residual cardiovascular risk. While monoclonal antibodies and RNA-based drugs offer effective, repeat-dose therapies, in vivo CRISPR editing could enable a one-time, lifelong correction of hypertriglyceridemia and mixed dyslipidemia. The main challenge ahead lies in ensuring safety, scalability, and equitable access if long-term efficacy and tolerability are confirmed in phase 3 trials.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"77-83"},"PeriodicalIF":2.7,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145767357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries. 高甘油三酯血症：来自新药临床试验和现实世界注册的最新信息。

IF 3.5 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-04-01 Epub Date: 2026-02-18 DOI: 10.1097/MED.0000000000000955

Mohamed Haseef, Stephen C H Li, Tobias Gaitt, Dick C Chan, Jing Pang, Gerald F Watts

{"title":"Hypertriglyceridemia: updates from clinical trials of new agents and real-world registries.","authors":"Mohamed Haseef, Stephen C H Li, Tobias Gaitt, Dick C Chan, Jing Pang, Gerald F Watts","doi":"10.1097/MED.0000000000000955","DOIUrl":"10.1097/MED.0000000000000955","url":null,"abstract":"Purpose of review: Hypertriglyceridemia (HTG) is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) and acute pancreatitis (AP). Early detection and treatment are important to prevent such complications. This review briefly outlines the etiology and novel treatments of HTG and recent findings from contemporary HTG registries.Recent findings: HTG is associated with an increased prevalence of cardiometabolic risk factors, including obesity, diabetes, and hepatic steatosis. Novel ribonucleic acid-based treatments for HTG have shown a substantial reduction in plasma triglycerides and a lower incidence of AP. A recent trial confirmed such benefit in patients with triglycerides >500 mg/dl (5.6 mmol/l), albeit with an increase in low-density lipoprotein-cholesterol, a reduction in remnant cholesterol and no change in apolipoprotein B. There is a need to harmonize the definitions of HTG and improve the care of individuals with severe HTG and familial chylomicronemia syndrome. New and evolving international registries are beginning to provide useful real-world data.Summary: Patient registries for HTG have provided valuable data for understanding the link between HTG and other cardiometabolic disorders; they can inform the planning of clinical services and the translation of the findings of new and future clinical trials of triglyceride-lowering therapies.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"66-76"},"PeriodicalIF":3.5,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146225821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Biomarkers and therapies to target endothelial dysfunction in type 2 diabetes: moving a step forward. 针对2型糖尿病内皮功能障碍的生物标志物和治疗：向前迈进了一步。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-10-29 DOI: 10.1097/MED.0000000000000933

Ying Jie Chee, Wann Jia Loh, Rinkoo Dalan

{"title":"Biomarkers and therapies to target endothelial dysfunction in type 2 diabetes: moving a step forward.","authors":"Ying Jie Chee, Wann Jia Loh, Rinkoo Dalan","doi":"10.1097/MED.0000000000000933","DOIUrl":"10.1097/MED.0000000000000933","url":null,"abstract":"Purpose of review: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality in people with type 2 diabetes mellitus (T2DM). Endothelial dysfunction is a precursor of atherosclerosis. This is a silent process that occurs over years. Focus on primary prevention to identify and target endothelial dysfunction early can slow down the atherosclerotic process and prevent ASCVD.Recent findings: Emerging blood-based methods include novel endothelial related biomarkers, such as endothelial specific extracellular vesicles, markers of endothelial regeneration and endothelial specific polygenic risk score. Physiology imaging-based method includes the flow-mediated dilation of the brachial artery, a noninvasive procedure that had gained attention for standardization in an international consensus guideline. Recognizing the role of endothelial function in ASCVD, studies are increasingly incorporating endothelial function biomarkers and FMD as surrogate markers of response. There is also emerging evidence on how nonpharmacological and pharmacological strategies improve endothelial function.Summary: Blood and imaging-based assessment of endothelial function is a promising area that can enhance early preventive efforts. Future studies to assess the incremental value of endothelial function assessment in contemporary longitudinal cohorts across diverse populations is necessary to identify the high-risk asymptomatic individuals who will benefit from intensive primary prevention.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"8-15"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145421418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The psychological dimension of obesity - an uncharted territory. 肥胖的心理层面——一个未知的领域。

IF 2.7 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-12-05 DOI: 10.1097/MED.0000000000000948

Stephen A Jiwanmall, Dheeraj Kattula

{"title":"The psychological dimension of obesity - an uncharted territory.","authors":"Stephen A Jiwanmall, Dheeraj Kattula","doi":"10.1097/MED.0000000000000948","DOIUrl":"10.1097/MED.0000000000000948","url":null,"abstract":"Purpose of review: To highlight the recent advancements in understanding the influence of psychological factors on the causation and management of obesity, which holds significance for clinical practice.Recent findings: This review explores developments in understanding psychological risk factors, sequelae, and treatments for obesity. Despite good evidence for psychological therapies in weight management, there are no standardized protocols for assessing patients requiring metabolic and bariatric surgery. Psychological therapies are synergistic with obesity medications.Summary: Obesity is a complex health issue with psychological dimensions. Stress, emotional dysregulation, and cognitive factors contribute to obesity. Stress's physiological impact on adipose tissue distribution and metabolic function, mediated by cortisol, demonstrates this interaction. Obesity leads to psychological consequences, including depression, low self-esteem, and reduced quality of life. The relationship between depression and obesity is modulated by demographic factors and biological mechanisms. Body composition reflects interactions between habits and cultural ideals, and medical models may increase stigma. Psychological interventions like cognitive-behavioral therapy and motivational interviewing effectively maintain weight loss. Psychological assessments before bariatric surgery are crucial for identifying mental health issues. This review highlights psychological dimensions in obesity prevention and treatment strategies.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"55-62"},"PeriodicalIF":2.7,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The evolution of C-peptide's role in diabetes care. c肽在糖尿病治疗中的作用演变。

IF 3.5 3区医学

Current Opinion in Endocrinology & Diabetes and Obesity Pub Date : 2026-02-01 Epub Date: 2025-12-08 DOI: 10.1097/MED.0000000000000947

Laura Briggs, Alexander Read, Sarah Darch, Emma L Williams, Wann Jia Loh, Julia S Kenkre

{"title":"The evolution of C-peptide's role in diabetes care.","authors":"Laura Briggs, Alexander Read, Sarah Darch, Emma L Williams, Wann Jia Loh, Julia S Kenkre","doi":"10.1097/MED.0000000000000947","DOIUrl":"10.1097/MED.0000000000000947","url":null,"abstract":"Purpose of review: Diabetes mellitus affects one in nine adults worldwide, with timely diagnosis and accurate classification being essential for patient management. C-peptide is an important biomarker in the diagnostic workup. As diabetes sub-typing and treatment options continue to evolve, this review will highlight the important aspects of C-peptide analysis and interpretation and additionally, evaluate its current and emerging clinical role.Recent findings: Several sample types and testing strategies such as fasting, random and stimulated C-peptide are available which are reviewed here. Random nonfasting C-peptide is convenient to perform in clinic and performs well compared to gold standard testing for classification of severe insulin deficiency and insulin dependence. C-peptide measurement may also be useful for classifying type 2 diabetes subtypes and in predicting response to treatment. Despite ongoing efforts towards standardization of C-peptide, variation still exists between analytical methods.Summary: This review summarizes recent literature relating to preanalytical, analytical and clinical aspects of C-peptide testing. Future research in this area may build on the role of C-peptide in predicting glycaemic control, clinical complications and response to pharmacotherapy.","PeriodicalId":10964,"journal":{"name":"Current Opinion in Endocrinology & Diabetes and Obesity","volume":" ","pages":"16-24"},"PeriodicalIF":3.5,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12746783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145699953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0